Cotadutide is an experimental drug for the treatment of type 2 diabetes mellitus. It lowers blood glucose levels by mimicking the human hormones glucagon-like peptide 1 and glucagon, which play a role in blood sugar regulation. The drug is a peptide that is injected under the skin.

Cotadutide is in Phase II clinical trials as of February 2021^[update]. Cotadutide, a therapeutic agent, was undergoing Phase II clinical trials. This stage of trials typically involves evaluating the drug's effectiveness and further assessing its safety in a larger group of participants, compared to earlier phases.^{[citation needed]}